Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5 trial
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial
NCT00200681 : Phase 3- IFM 2005-01: Velcade/Dex Vs Vincristine/Adriamycin/Dex (VAD) for MM
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
NCT00081939: UARK 2003-33, Total Therapy III
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
IFM trial: Conventional chemo or high-dose therapy and auto bone marrow transplantation - NEJM 1996
Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999